{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T03:25:11Z","timestamp":1768274711748,"version":"3.49.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archivos de la Sociedad Espa\u00f1ola de Oftalmolog\u00eda"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.oftal.2020.05.010","type":"journal-article","created":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T18:05:20Z","timestamp":1593626720000},"page":"386-395","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Neuritis \u00f3pticas desmielinizantes y autoinmunes"],"prefix":"10.1016","volume":"95","author":[{"given":"A.","family":"Garc\u00eda Ortega","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.J.","family":"Monta\u00f1ez Campos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Sanchez-Dalmau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.oftal.2020.05.010_bib0260","series-title":"Neuropat\u00edas \u00f3pticas: diagnostico y tratamiento","first-page":"177","article-title":"Neuritis \u00f3pticas","author":"Savino","year":"2002"},{"key":"10.1016\/j.oftal.2020.05.010_bib0265","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1001\/archopht.1991.01080120057025","volume":"109","year":"1991","journal-title":"Arch Ophthalmol."},{"key":"10.1016\/j.oftal.2020.05.010_bib0270","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1474-4422(13)70259-X","article-title":"Optic neuritis","volume":"13","author":"Toosy","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.oftal.2020.05.010_bib0275","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s00415-014-7266-2","article-title":"Is the incidence of optic neuritis rising? Evidence from an epidemiological study in Barcelona (Spain), 2008-2012","volume":"261","author":"Mart\u00ednez-Lapiscina","year":"2014","journal-title":"J Neurol."},{"key":"10.1016\/j.oftal.2020.05.010_bib0280","series-title":"Clinical Neuro-Ophthalmology. The essentials","first-page":"599","article-title":"Optic neuritis","author":"RW","year":"1998"},{"key":"10.1016\/j.oftal.2020.05.010_bib0285","series-title":"Color atlas & synopsis of clinical ophthalmology","first-page":"64","author":"Savino","year":"2012"},{"key":"10.1016\/j.oftal.2020.05.010_bib0290","doi-asserted-by":"crossref","unstructured":"Noval S, Rebolleda G. P\u00e9rdida de vision monocular con fondo de ojo normal \u2013 Neuropat\u00eda \u00f3tica retrobulbar. En: Rebolleda G, Mu\u00f1oz Negrete FJ. Protocolos en Neuro-oftalmolog\u00eda. Madrid: MACLINE SL. 2010:77-84.","DOI":"10.4321\/S0365-66912009000300008"},{"key":"10.1016\/j.oftal.2020.05.010_bib0295","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ophtha.2006.10.003","article-title":"Optical Coherence Tomography in Optic Neuritis","volume":"114","author":"Noval","year":"2007","journal-title":"Ophthalmology."},{"key":"10.1016\/j.oftal.2020.05.010_bib0300","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.3390\/ijms17111894","article-title":"Optical Coherence Tomography and Magnetic Resonance Imaging in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder","volume":"17","author":"Manogaran","year":"2016","journal-title":"Int J Mol Sci."},{"key":"10.1016\/j.oftal.2020.05.010_bib0305","first-page":"727","article-title":"Multiple Sclerosis Risk After Optic Neuritis: Final Optic Neuritis Treatment Trial Follow-Up","volume":"65","author":"Brodsky","year":"2008","journal-title":"Arch Neurol."},{"key":"10.1016\/j.oftal.2020.05.010_bib0310","author":"Kang","year":"2019","journal-title":"Optic Neuritis Imaging"},{"key":"10.1016\/j.oftal.2020.05.010_bib0315","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.survophthal.2019.06.001","article-title":"Critical review: Typical and atypical optic neuritis","volume":"64","author":"Abel","year":"2019","journal-title":"Surv Ophthalmol."},{"key":"10.1016\/j.oftal.2020.05.010_bib0320","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jneuroim.2016.09.007","article-title":"Different etiologies and prognoses of optic neuritis in demyelinating diseases","volume":"299","author":"Akaishi","year":"2016","journal-title":"J Neuroimmunol."},{"key":"10.1016\/j.oftal.2020.05.010_bib0325","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.oftal.2020.05.010_bib0330","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/archopht.1993.01090060061023","article-title":"Optic Neuritis Treatment Trial. One-year Follow-Up Results","volume":"111","author":"Beck","year":"1993","journal-title":"Arch Ophthalmol."},{"key":"10.1016\/j.oftal.2020.05.010_bib0335","article-title":"Corticosteroids for treating optic neuritis","volume":"2015","author":"Gal","year":"2015","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.oftal.2020.05.010_bib0340","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/S0140-6736(15)61137-0","article-title":"Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial","volume":"386","author":"Le Page","year":"2015","journal-title":"Lancet."},{"key":"10.1016\/j.oftal.2020.05.010_bib0345","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1001\/jamaneurol.2018.0024","article-title":"Effect of treating acute optic neuritis with bioequivalent oral vs intravenous corticosteroids: a randomized clinical trial","volume":"75","author":"Morrow","year":"2018","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.oftal.2020.05.010_bib0350","first-page":"9","article-title":"Case for a new corticosteroid treatment trial in optic neuritis: review of updated evidence","volume":"0","author":"Petzold","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"10.1016\/j.oftal.2020.05.010_bib0355","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/00041327-200112000-00016","volume":"21","author":"Beck","year":"2001","journal-title":"J Neurophthalmology."},{"key":"10.1016\/j.oftal.2020.05.010_bib0360","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/ana.10148","article-title":"Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses","volume":"51","author":"Beck","year":"2002","journal-title":"Ann Neurol."},{"key":"10.1016\/j.oftal.2020.05.010_bib0365","first-page":"144","article-title":"Protocolo diagn\u00f3stico-terap\u00e9utico de la neuritis \u00f3ptica en adultos","volume":"17","author":"Planas Dom\u00e8nech","year":"2009","journal-title":"Annals d\u2019oftalmologia."},{"issue":"4\u20135","key":"10.1016\/j.oftal.2020.05.010_bib0370","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.autrev.2014.01.009","article-title":"Diagnosis and classification of autoimmune optic neuropathy","volume":"13","author":"Petzold","year":"2014","journal-title":"Autoimmun Rev."},{"key":"10.1016\/j.oftal.2020.05.010_bib0375","doi-asserted-by":"crossref","DOI":"10.1177\/1756286418762083","article-title":"Defining distinct features of anti-MOG antibody associated central nervous system demyelination","volume":"11","author":"Weber","year":"2018","journal-title":"Ther Adv Neurol Disord."},{"key":"10.1016\/j.oftal.2020.05.010_bib0380","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/B978-0-444-52001-2.00025-X","article-title":"Neuromyelitis optica (Devic's syndrome)","volume":"122","author":"Wingerchuk","year":"2014","journal-title":"Handb Clin Neurol."},{"key":"10.1016\/j.oftal.2020.05.010_bib0385","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","author":"Wingerchuk","year":"2015","journal-title":"Neurology."},{"key":"10.1016\/j.oftal.2020.05.010_bib0390","doi-asserted-by":"crossref","first-page":"e0167473","DOI":"10.1371\/journal.pone.0167473","article-title":"Retinal Morphology and Sensitivity Are Primarily Impaired in Eyes with Neuromyelitis Optica Spectrum Disorder (NMOSD)","volume":"11","author":"Akiba","year":"2016","journal-title":"PLoS One."},{"key":"10.1016\/j.oftal.2020.05.010_bib0395","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/cen3.12345","article-title":"M\u00fcller cells and retinal axons can be primary targets in experimental neuromyelitis optica spectrum disorder","volume":"8","author":"Zeka","year":"2017","journal-title":"Clin Exp Neuroimmunol."},{"key":"10.1016\/j.oftal.2020.05.010_bib0400","first-page":"660","article-title":"Paraneoplastic neuromyelitis optica spectrum disorders: Three new cases and a review of the literature","author":"Cai","year":"2016","journal-title":"Int J Neurosci."},{"key":"10.1016\/j.oftal.2020.05.010_bib0405","article-title":"Aquaporin-4 IgG seropositivity is associated with worse visual outcomes after optic neuritis than MOG-IgG seropositivity and multiple sclerosis, independent of macular ganglion cell layer thinning","author":"Sotirchos","year":"2019","journal-title":"Mult Scler."},{"key":"10.1016\/j.oftal.2020.05.010_bib0410","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1186\/s12974-018-1335-x","article-title":"Chronic relapsing inflammatory optic neuropathy (CRION): a manifestation of myelin oligodendrocyte glycoprotein antibodies","volume":"15","author":"Lee","year":"2018","journal-title":"J Neuroinflammation."},{"key":"10.1016\/j.oftal.2020.05.010_bib0415","doi-asserted-by":"crossref","first-page":"003","DOI":"10.1055\/s-0037-1604404","article-title":"MOG Spectrum Disorders and Role of MOG-Antibodies in Clinical Practice","volume":"49","author":"Hennes","year":"2018","journal-title":"Neuropediatrics."},{"key":"10.1016\/j.oftal.2020.05.010_bib0420","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1007\/s00415-018-9122-2","article-title":"Neurological update: MOG antibody disease","volume":"266","author":"Wynford-Thomas","year":"2019","journal-title":"J Neurol."},{"key":"10.1016\/j.oftal.2020.05.010_bib0425","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.3389\/fimmu.2018.02753","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disorders: Toward a new spectrum of inflammatory demyelinating CNS disorders?","author":"Di Pauli","year":"2018","journal-title":"Front Immunol."},{"key":"10.1016\/j.oftal.2020.05.010_bib0430","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3389\/fneur.2018.00217","article-title":"MOG-IgG-associated optic neuritis, encephalitis, and myelitis: Lessons learned from neuromyelitis optica spectrum disorder","author":"Rodrigues dos Passos","year":"2018","journal-title":"Front Neurol."},{"key":"10.1016\/j.oftal.2020.05.010_bib0435","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","article-title":"Myelin oligodendrocyte glycoprotein antibodies in neurological disease","volume":"15","author":"Reindl","year":"2019","journal-title":"Nat Rev Neurol."},{"key":"10.1016\/j.oftal.2020.05.010_bib0440","doi-asserted-by":"crossref","DOI":"10.1136\/bjophthalmol-2019-314845","article-title":"MOG-Ab prevalence in optic neuritis and clinical predictive factors for diagnosis","author":"Ducloyer","year":"2020","journal-title":"Br J Ophthalmol."},{"key":"10.1016\/j.oftal.2020.05.010_bib0445","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.msard.2019.01.021","article-title":"Radiological characteristics of myelin oligodendrocyte glycoprotein antibody disease","volume":"29","author":"Salama","year":"2019","journal-title":"Mult Scler Relat Disord."},{"key":"10.1016\/j.oftal.2020.05.010_bib0450","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.msard.2018.12.035","article-title":"Clinical significance of assaying anti-MOG antibody in cerebrospinal fluid in MOG-antibody-associated diseases: A case report","volume":"28","author":"Aoe","year":"2019","journal-title":"Mult Scler Relat Disord."},{"key":"10.1016\/j.oftal.2020.05.010_bib0455","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1212\/WNL.0000000000007312","article-title":"Tocilizumab treatment in severe recurrent anti-MOG-Associated optic neuritis","volume":"92","author":"Hayward-Koennecke","year":"2019","journal-title":"Neurology."},{"key":"10.1016\/j.oftal.2020.05.010_bib0460","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jneuroim.2018.09.010","article-title":"Recurrent optic neuritis \u2013 Different patterns in multiple sclerosis, neuromyelitis optica spectrum disorders and MOG-antibody disease","volume":"324","author":"Lotan","year":"2018","journal-title":"J Neuroimmunol."},{"key":"10.1016\/j.oftal.2020.05.010_bib0465","first-page":"1649","article-title":"Optical coherence tomography in central nervous system demyelinating diseases related optic neuritis","volume":"11","author":"Mekhasingharak","year":"2018","journal-title":"Int J Ophthalmol."},{"key":"10.1016\/j.oftal.2020.05.010_bib0470","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.survophthal.2019.08.001","article-title":"Optic neuritis in the era of biomarkers","volume":"65","author":"Chen","year":"2020","journal-title":"Surv Ophthalmol."},{"key":"10.1016\/j.oftal.2020.05.010_bib0475","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.msard.2018.09.001","article-title":"Recurrent Schilder's disease","volume":"26","author":"Dunn-Pirio","year":"2018","journal-title":"Mult Scler Relat Disord."},{"key":"10.1016\/j.oftal.2020.05.010_bib0480","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.pediatrneurol.2019.06.017","article-title":"Acute Disseminated Encephalomyelitis in Children: An Updated Review Based on Current Diagnostic Criteria","volume":"100","author":"Cole","year":"2019","journal-title":"Pediatr Neurol."},{"key":"10.1016\/j.oftal.2020.05.010_bib0485","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.autrev.2013.10.003","article-title":"The spectrum of post-vaccination inflammatory CNS demyelinating syndromes","volume":"13","author":"Karussis","year":"2014","journal-title":"Autoimmun Rev."},{"key":"10.1016\/j.oftal.2020.05.010_bib0490","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1212\/NXI.0000000000000270","article-title":"Optic neuropathy associated with systemic sarcoidosis","volume":"3","author":"Kidd","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflammation."},{"key":"10.1016\/j.oftal.2020.05.010_bib0495","doi-asserted-by":"crossref","first-page":"169","DOI":"10.7861\/clinmedicine.19-2-169","article-title":"Neuromyelitis optica spectrum disorders","volume":"19","author":"Huda","year":"2019","journal-title":"Clin Med (Lond.)."},{"key":"10.1016\/j.oftal.2020.05.010_bib0500","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1001\/jamaneurol.2014.3602","article-title":"Antibodies to aquaporin 4, myelin-oligodendrocyte glycoprotein, and the glycine receptor \u03b11 subunit in patients with isolated optic neuritis","volume":"72","author":"Martinez-Hernandez","year":"2015","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.oftal.2020.05.010_bib0505","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1080\/08820538.2019.1620806","article-title":"For Massachusetts Eye and Ear Special Issue: Updates on Therapies for Multiple Sclerosis for the Ophthalmologist","volume":"34","author":"Bakaeva","year":"2019","journal-title":"Semin Ophthalmol."},{"key":"10.1016\/j.oftal.2020.05.010_bib0510","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s40265-018-1039-7","article-title":"Pharmacotherapy for Neuromyelitis Optica Spectrum Disorders: Current Management and Future Options","volume":"79","author":"Collongues","year":"2019","journal-title":"Drugs."}],"container-title":["Archivos de la Sociedad Espa\u00f1ola de Oftalmolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0365669120301866?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0365669120301866?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T23:44:10Z","timestamp":1759794250000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0365669120301866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":51,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S0365669120301866"],"URL":"https:\/\/doi.org\/10.1016\/j.oftal.2020.05.010","relation":{},"ISSN":["0365-6691"],"issn-type":[{"value":"0365-6691","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neuritis \u00f3pticas desmielinizantes y autoinmunes","name":"articletitle","label":"Article Title"},{"value":"Archivos de la Sociedad Espa\u00f1ola de Oftalmolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oftal.2020.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Sociedad Espa\u00f1ola de Oftalmolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}